Cross-Sectional Characterization of Albumin Glycation State in Cerebrospinal Fluid and Plasma from Alzheimer's Disease Patients

J Prev Alzheimers Dis. 2019;6(2):139-143. doi: 10.14283/jpad.2018.48.


We determined albumin post-translational modifications (PTMs) by mass spectrometry (MS) in plasma and cerebrospinal fluid (CSF) from 31 Alzheimer's disease (AD) patients (with 27 samples of paired plasma-CSF from the same patients). Results were cross-sectionally compared with healthy controls. For percentage of relative intensity of glycated isoforms, plasma albumin was globally more glycated in AD patients than in healthy controls (P<0.01). MS results in plasma were confirmed by a quantitative enzymatic assay (Lucica GA-L) for albumin early-glycation detection. In CSF there were no global glycation differences detected by MS, although a different pattern of glycated isoforms was observed. Oxidized+glycated and cysteinylated+glycated isoforms were increased in both plasma and CSF of AD patients in comparison with healthy controls (P<0.001). Furthermore, AD patients showed higher glycation in plasma than in CSF (P<0.01). Our data support the role of glycation and oxidative stress in AD.

Keywords: Albumin; Alzheimer’s disease; cerebrospinal fluid; glycation status; plasma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Alzheimer Disease / cerebrospinal fluid
  • Alzheimer Disease / metabolism*
  • Case-Control Studies
  • Chromatography, Liquid
  • Female
  • Glycation End Products, Advanced
  • Humans
  • Male
  • Mass Spectrometry
  • Middle Aged
  • Oxidation-Reduction
  • Oxidative Stress*
  • Protein Processing, Post-Translational*
  • Serum Albumin / cerebrospinal fluid
  • Serum Albumin / metabolism*


  • Glycation End Products, Advanced
  • Serum Albumin
  • glycated serum albumin